WSG Stock Chart & Stats
€0.22
€0.00(0.00%)
At close: 4:00 PM EDT
€0.22
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.19 - €0.29
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€801.52M
Enterprise Value€10.41K
Total Cash (Recent Filing)€5.16B
Total Debt (Recent Filing)€2.49B
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding5,035,802,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.46
Price to Sales (P/S)0.64
P/FCF Ratio4.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€1.59B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA conservative balance sheet with falling debt and substantial equity reduces refinancing risk and preserves financial flexibility. Over a multi-month horizon this supports the company’s ability to fund operations, absorb shocks, and pursue strategic investments or restructuring without immediate capital markets reliance.
Strong Recent Operating & Free Cash FlowSustained positive operating and free cash flow in 2024–2025 implies the company can internally generate liquidity to cover capex, service liabilities, and support distributions. For the next several months this cash conversion provides a runway to execute turnaround actions and maintain capital allocation without immediate external financing.
High Dividend YieldA high dividend yield offers meaningful shareholder income and can attract yield-oriented investors, supporting long-term investor base stability. Coupled with recent positive free cash flow and low leverage, the yield can be durable if cash conversion remains consistent, helping preserve shareholder returns while the business stabilizes.
Bears Say
Profitability DeteriorationA structural decline to a net loss in 2025 undermines the company’s ability to generate returns and reinvest in growth. Over the next several months this loss profile can limit operational investments, strain margins further, reduce retained earnings, and challenge the sustainability of dividends and strategic initiatives until profitability recovers.
Inconsistent Revenue TrendsNegative and uneven revenue growth indicates unstable demand or pricing power, making future top-line forecasting and scale economics uncertain. Over a 2–6 month horizon, this inconsistency complicates margin recovery, capacity planning, and the ability to lock in durable revenue streams needed for a sustained operational turnaround.
Volatile Cash Flow And Margin CompressionHistoric free-cash-flow volatility and recent margin compression reduce the reliability of internal funding and heighten sensitivity to working-capital swings. This limits the firm’s capacity to consistently fund capex, dividends, and strategic programs over months, increasing the risk that recent positive cash reads are temporary rather than structural.
China Traditional Chinese Medicine Holdings Co News
WSG FAQ
What was China Traditional Chinese Medicine Holdings Co Ltd’s price range in the past 12 months?
China Traditional Chinese Medicine Holdings Co Ltd lowest stock price was €0.18 and its highest was €0.29 in the past 12 months.
What is China Traditional Chinese Medicine Holdings Co Ltd’s market cap?
China Traditional Chinese Medicine Holdings Co Ltd’s market cap is €801.52M.
When is China Traditional Chinese Medicine Holdings Co Ltd’s upcoming earnings report date?
China Traditional Chinese Medicine Holdings Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 24 days.
How were China Traditional Chinese Medicine Holdings Co Ltd’s earnings last quarter?
China Traditional Chinese Medicine Holdings Co Ltd released its earnings results on Mar 20, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is China Traditional Chinese Medicine Holdings Co Ltd overvalued?
According to Wall Street analysts China Traditional Chinese Medicine Holdings Co Ltd’s price is currently Overvalued.
Does China Traditional Chinese Medicine Holdings Co Ltd pay dividends?
China Traditional Chinese Medicine Holdings Co Ltd does not currently pay dividends.
What is China Traditional Chinese Medicine Holdings Co Ltd’s EPS estimate?
China Traditional Chinese Medicine Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Traditional Chinese Medicine Holdings Co Ltd have?
China Traditional Chinese Medicine Holdings Co Ltd has 5,035,802,000 shares outstanding.
What happened to China Traditional Chinese Medicine Holdings Co Ltd’s price movement after its last earnings report?
China Traditional Chinese Medicine Holdings Co Ltd reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.505%.
Which hedge fund is a major shareholder of China Traditional Chinese Medicine Holdings Co Ltd?
Currently, no hedge funds are holding shares in DE:WSG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Traditional Chinese Medicine Holdings Co Ltd
China Traditional Chinese Medicine Holdings Co. Limited functions as an investment holding company, primarily focusing on the research, development, and sale of traditional Chinese medicine and other pharmaceutical goods across the People's Republic of China. The company's product range includes medicinal granules, finished pharmaceutical preparations, pre-portioned decoction materials, and various healthcare products. Furthermore, its operations extend to the cultivation and management of Chinese medicinal herbs, the manufacturing of traditional Chinese medicines, and the trading of pharmaceutical products. It also delivers marketing, advertising, and consulting services related to TCM, and operates retail outlets for pharmaceuticals and decoction products. Property leasing services represent another facet of its business. The company distributes its products to healthcare facilities and retail pharmacies. Established in 1573 and headquartered in Wan Chai, Hong Kong, the firm was formerly known as China Traditional Chinese Medicine Co. Limited before adopting its current name in July 2016.
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Wai Yuen Tong Medicine Holdings Limited
―
Grand Pharmaceutical Group Limited
―
Golden Throat Holdings Group Co Ltd
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―